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Heterodimerization of AML1/ETO with CBFβ is required for
leukemogenesis but not for myeloproliferation
VN Thiel1,7, BD Giaimo2,7, P Schwarz1, K Soller3, V Vas3, M Bartkuhn4, TJ Blätte5, K Döhner5, L Bullinger5, T Borggrefe2, H Geiger3,6
and F Oswald1
The AML1/Runx1 transcription factor and its heterodimerization partner CBFβ are essential regulators of myeloid differentiation.
The chromosomal translocation t(8;21), fusing the DNA binding domain of AML1 to the corepressor eight-twenty-one (ETO), is
frequently associated with acute myeloid leukemia and generates the AML1/ETO (AE) fusion protein. AE represses target genes
usually activated by AML1 and also affects the endogenous repressive function of ETO at Notch target genes. In order to analyze
the contribution of CBFβ in AE-mediated leukemogenesis and deregulation of Notch target genes, we introduced two point
mutations in a leukemia-initiating version of AE in mice, called AE9a, that disrupt the AML1/CBFβ interaction (AE9aNT). We report
that the AE9a/CBFβ interaction is not required for the AE9a-mediated aberrant expression of AML1 target genes, while
upregulation/derepression of Notch target genes does require the interaction with CBFβ. Using retroviral transduction to express
AE9a in murine adult bone marrow-derived hematopoietic progenitors, we observed that both AE9a and AE9aNT lead to increased
myeloproliferation in vivo. However, both development of leukemia and long-term replating capacity are only observed with AE9a
but not with AE9aNT. Thus, deregulation of both AML1 and Notch target genes is required for the development of AE9a-driven
leukemia.
Leukemia (2017) 31, 2491–2502; doi:10.1038/leu.2017.105
INTRODUCTION
Acute myeloid leukemia (AML) requires the cooperation of
proliferative signals in hematopoietic stem and progenitor cells
and defects in myeloid differentiation.1,2 AML is genetically
heterogeneous and frequently characterized by chromosomal
rearrangements that produce fusion proteins with aberrant
transcriptional regulatory activities. The t(8;21)(q22;q22) transloca-
tion, present in 10–15% of AML cases, generates the AML1/ETO
(AE) fusion protein. Expression of the AE fusion protein in vivo
induces a pre-leukemic state,3,4 but the underlying molecular and
biological mechanisms used by AE for AML initiation still remain
unclear.
The transcription factor AML1 (also known as Runx1) is
an essential regulator of both fetal and adult hematopoiesis.5,6
AML1 is required for the development of hematopoietic stem
and progenitor cells.5 The DNA-binding Runt domain of AML1
heterodimerizes with the CBFβ protein, forming a complex
called core binding factor. The consensus DNA-binding site
of core binding factor has been identiﬁed as a 7 bp sequence
‘TGTGGTPy’.7,8 Eight-twenty-one (ETO, also known as MTG8)
protein is a member of the MTG family of transcriptional
corepressors.9 Being the homolog of the Drosophila melanogaster
protein Nervy,10 the ETO protein contains conserved nervy homo-
logy regions (NHR). NHR2 forms an amphipathic helix important
for homodimerization, whereas NHR4 contains two putative
zinc ﬁngers, required for the interaction with nuclear receptor
corepressor 1 and nuclear receptor corepressor 2 (also called
SMRT (silencing mediator for retinoid or thyroid-hormone
receptors))11,12 linking ETO to histone deacetylases.12,13
The t(8;21) translocation fuses the Runt domain of AML1 in frame
with almost all of the ETO protein14–17 (see also Figure 1a), leading to
deletion of the carboxy-terminal transactivation domain of AML1.
The resulting AE protein binds to AML1 binding sites,18 but, in
contrast to AML1, represses its target genes.19,20 The exact role for
CBFβ in the transformation process driven by AE is still unclear.21–23
Different mouse models have been used to investigate the
function of AE. The knock-in of AE in the endogenous AML1 locus
inhibited hematopoiesis, resulting in lethality.24,25 A conditional
AE knock-in approach resulted in enhanced replating capacity of
myeloid progenitors without blocking their differentiation or
induction of leukemia.3,26 Furthermore, AE requires additional
mutations to induce leukemogenesis in a murine model in vivo.4
Two more recently identiﬁed distinct carboxy-terminal truncation
variants of AE (AEtr and AE9a) though directly induce leukemia in
mice.27–29 While AEtr is generated as consequence of a single-
nucleotide insertion in mice,27 AE9a is a splice variant detected in
AML patients and coexpressed with the full-length AE.28 Surpris-
ingly, the repressive NHR3 and NHR4 domains are deleted in AE9a,
indicating that, in contrast to previous suggestions, AE does not
primarily act as a dominant negative regulator of AML1 target
genes to induce leukemia.25,30 We already demonstrated that ETO
also represses, in a complex with the RBP-J binding protein SHARP
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(SMRT and HDAC associated repressor protein, also called Spen),
Notch target genes, and this repressive function is impaired by
AE.31 In order to further investigate the molecular mechanisms of
AE9a-dependent transformation, here we dissected its dual role in
the deregulation of the AML1-activating and the ETO-repressing
gene regulatory role. Our data demonstrate that deregulation
of both Notch and AML1 target genes is required for leukemia
initiation by AE9a.
MATERIALS AND METHODS
Cell culture and preparation of cell extracts
Cell lines HEK-293 (ATCC CRL 1573), HeLa (ATCC CCL 2) and 3T3 (ATCC CRL
1658), as well as the Phoenix packaging cells (Orbigen, Inc., San Diego,
CA, USA), were grown in Dulbecco’s Modiﬁed Eagle Medium (Thermo Fisher
Scientiﬁc/Gibco, Waltham, MA, USA) supplemented with 10% fetal calf serum,
and penicillin/streptomycin. HoxB4 cells (kindly provided by Drs Simona
Saccani and Dominic van Essen and described in Stump et al.32) were grown
in Iscove’s Modiﬁed Dulbecco Medium (Thermo Fisher Scientiﬁc/Gibco)
supplemented with 2% fetal calf serum, 1% interleukin 3, 0.5% interleukin 6,
20 ng/ml stem cell factor, 0.3 mg/l peptone, 5 mg/l insulin, nonessential
amino acids, β-mercaptoethanol and penicillin/streptomycin. Cells were
grown at 37 °C with 5% CO2. For western blot and coimmunoprecipitation
experiments, whole-cell lysates were prepared as previously described.31
Protein concentrations were determined using the Bradford assay method
(Bio-Rad, Hercules, CA, USA). Details on the retroviral infection of HoxB4 cells
are provided in Supplementary Information.
DNA transfection
HEK-293 and HeLa cells were transfected using the Nanofectin transfection
reagent (PAA, Pasching, Austria). For transfection of Phoenix cells, the
Calcium Phosphate Transfection Kit (Thermo Fisher Scientiﬁc/Invitrogen,
Waltham, MA, USA) was used. All transfections were performed according
to the manufacturer’s instructions.
Plasmids
The following plasmids were previously described: pGa981/6, pcDNA3-Flag-
SPOC, pcDNA3-RBP;33 pcDNA3-Flag-SPOC pcDNA3-F3, pcDNA3-F3-AML1-ETO,
pcDNA3-AML1-ETO(tr)-GFP;31 pcDNA3-Flag-SPOC (Y3602A), pcDNA3-Flag-
SPOC (K3516A), pcDNA3-Flag-SPOC (R3552A/R3554A), pcDNA3-RBP-SPOC
pcDNA3-RBP-SPOC (Y3602A), pcDNA3-RBP-SPOC (K3516A), pcDNA3-RBP-
SPOC (R3552A/R3554A).34 The plasmid pMYs-IRES-GFP was commercially
Figure 1. AE but not AE9aNT forms a heterodimer with CBFβ but both proteins bind to DNA. (a) Representation of the proteins used in this
study: Full-length AE, AEtr, splice-variant AE9a and DNA-binding Runt domain of AML1. The arrows indicate the location of the two mutations
within the Runt domain, asparagine 109 (N109) and threonine 161 (T161) to alanines. (b) Coimmunoprecipitation experiments of endogenous
CBFβ together with wt, single mutant (N or T) or double mutant (NT) of Runt, AE, AEtr or AE9a. The wt proteins (runt, AE, AEtr and AE9a)
strongly interact with endogenous CBFβ (upper panels, lanes 1, 5, 9 and 13), whereas single N or Tmutants interact only weakly (upper panels,
lanes 2, 3, 6, 7, 10 and 11); the NT double mutant no longer binds to CBFβ (upper panels, lanes 4, 8, 12 and 14). Input controls are shown in the
lower panels. Flag-ETO was used as negative control (lane 15). The asterisk denotes the light chain of the antibody used for
immunoprecipitation. (c) Electrophoretic mobility shift assays showing that Runt and Runt NT (lanes 3 to 6) as well as AE9a and AE9aNT (lanes
11 to 14) bind to DNA (see label ‘A’). Addition of an anti-Flag antibody resulted in super shifted complexes (see label ‘B’). Flag-tagged protein
expression was veriﬁed by western blot shown in Supplementary Figures S1d and e.
Notch target genes contribute to AML
VN Thiel et al
2492
Leukemia (2017) 2491 – 2502
achieved from Cell Biolabs, San Diego, CA, USA. Sequence information of all
additional vectors used in this study is available on request.
Coimmunoprecipitation experiments
The coimmunoprecipitation experiments were carried out essentially
as previously described.35 Brieﬂy, cells were lysed 24 h after transfection
with 600 μl CHAPS lysis buffer consisting of 10 mM CHAPS, 50 mM
Tris-HCl (pH 7.8), 150 mM NaCl, 5 mM NaF, 1 mM DTT, 0.5 mM PMSF and
40 μl/ml 'Complete Mix' protease inhibitor cocktail (Roche, Basel, Switzer-
land). Extracts were incubated overnight with 40 μl agarose-conjugated
anti-Flag antibody (M2, Sigma-Aldrich, St Louis, MO, USA) at 4 °C.
Precipitates were washed 6 to 8 times with CHAPS lysis buffer and ﬁnally
resuspended in SDS-polyacrylamide gel loading buffer. Proteins were
resolved via SDS-PAGE and analyzed via western blotting.
GST pulldown assays
GST fusion proteins were expressed in Escherichia coli strain BL21
(Stratagene, San Diego, CA, USA) and stored as whole bacterial lysates at
− 80 °C. For GST pulldown assays, proteins were translated in vitro in the
presence of [35S]-Methionine using the TNT-assay (#L4610) from Promega
(Madison, WI, USA) according to the manufacturer’s instructions. Pulldown
experiments were carried out essentially as previously described.31
Electromobility shift assay
Transfected HEK-293 cells were lysed using a freeze–thaw method in a lysis
buffer containing 0.2 mM EDTA, 20 mM HEPES (pH 7.9), 1.5 mM MgCl2, 420 mM
NaCl and 25% glycerol. Six micrograms of protein lysate was incubated with
1.5 μg poly(dI-dC) (GE Healthcare, Chalfont St Giles, UK) and approximately
0.5 ng of [32P]-dCTP-labeled oligonucleotides in a binding buffer consisting of
0.5 mM DTT, 5 mM EDTA, 5 mM MgCl2, 250 mM NaCl, 50 mM Tris-HCl (pH 7.5)
and 25% glycerol. The sequence of the double-stranded oligonucleotide
Runt2X (5′-CTAGAGAGTGGTGTGGTAGTGCGGTCGGGGT-3′) corresponds to the
AE9a-binding sites published in Okumura et al.36 Super shifting of complexes
was achieved by adding 1 μg of anti-Flag antibody (M5, Sigma-Aldrich,
#F4042). The reaction products were resolved at room temperature in a 7.5%
PAGE with 0.5× Tris-Borate-EDTA. Gels were dried and exposed to X-ray ﬁlms
(GE Healthcare).
RNA extraction, RT-PCR and qPCR
Total RNA was puriﬁed using Trizol reagent (Thermo Fisher Scientiﬁc/
Ambion, Waltham, MA, USA, #15596018) according to the manufacturer’s
instructions and 1 mg of RNA was retro-transcribed in cDNA using random
hexamers and M-MuLV reverse transcriptase (NEB, Ipswich, MA, USA). qPCR
reactions were performed with Absolute QPCR ROX Mix (Thermo Fisher
Scientiﬁc, Waltham, MA, USA) #AB-1139, gene-speciﬁc oligonucleotides
and double-dye probes (listed in Supplementary Table S1) and analyzed
using the 7300 ABI PRISM sequence detector system (Thermo Fisher
Scientiﬁc/Applied Biosystems, Waltham, MA, USA). Data were normalized
to either the housekeeping gene TATA Box Binding Protein or
Glyceraldehyde-3-Phosphate-Dehydrogenase.
Retroviral particle production
The pMY vectors (IRES-GFP, AE9a IRES-GFP- and AE9aNT IRES-GFP) were
transiently transfected into Phoenix packaging cells. At 24, 36 and 60 h
after transfection, retrovirus containing supernatants were collected,
ﬁltered (Whatman, #10462100) and stored at − 80 °C. Viral supernatants
were titrated on 3T3 cells.
Animals
C57BL/6 and B6.SJL-Ptprca Pep3b/BoyJ mice were either obtained from in-
house colonies of the animal facility of Ulm or purchased from Janvier. All
animal experiments were carried out in cooperation with the animal facility
at the University of Ulm in accordance with the ‘Tierschutzgesetz §8,
Abs. 1 und 3’. Experiments were approved by the ‘Regierungspräsidium
Tübingen’.
Retroviral gene transfer and bone marrow (BM) transplantation
Retroviral gene transfer and BM transplantation were carried out basically
as described in Vas et al.37 A detailed protocol is provided in
Supplementary Information.
Flow cytometry analysis of peripheral blood (PB), BM and spleen
samples
Chimerism and engraftment in PB was determined in recipient mice every
6 weeks post transplantation. For end-point in-depth analysis, mice were
killed and BM and spleen cells were isolated. Chimerism and engraftment
in BM and spleen cells were analyzed as described above. After red blood
cell lysis with standard NH4Cl buffer, cells were analyzed on a LSRII ﬂow
cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). Detailed staining
protocols and antibodies are provided in Supplementary Information.
Colony-forming cell assays
GFP-positive hematopoietic progenitors from retroviral transduced BM
cells were ﬂuorescence-activated cell scanner sorted and 400 cells were
seeded on methylcellulose-based semi-solid media supplemented with
cytokine mixtures (Stem Cell Technologies, Vancouver, BC, Canada).
Colony-forming progenitors were scored every 7 days and replated in
new methylcellulose medium at a concentration of 1 × 104 cells/well (six-
well plates). Experiments were performed in triplicates.
Luciferase assay
HeLa cells (5 × 104) were transfected in 48-well plates with 0.5 μg of
reporter plasmid DNA and different amounts of the desired expression
plasmids. Luciferase activity was determined from at least three indepen-
dent transfections using 10 μl of cleared lysate in a LB 9501 luminometer
(Berthold Technologies, Bad Wildbad, Germany) by using the luciferase
assay system from Promega.
Mouse survival and statistical analyses
The Kaplan–Meier survival curve and statistical analyses were performed using
GraphPad Prism4 software (GraphPad Software, San Diego, CA, USA).
RESULTS
Mutant AE9aNT lacks CBFβ-interaction ability but still binds to
DNA
Based on the published structure of the AML1/CBFβ complex,38 we
generated mutants of AE9a where asparagine 109 and threonine
161 were mutated to alanines (N109A and T161A, respectively)
(indicated by arrows in Figure 1a) and tested their inﬂuence on
the AE9a/CBFβ interaction (Figure 1b). Coimmunoprecipitation of
Flag-tagged Runt domain of AML1, AE, AEtr and AE9a, each with
either a single N109A (N) or T161A (T) mutation or N109A/T161A
double point mutations (NT), revealed that Runt, AE, AEtr and
AE9a wild-type (wt) proteins bind strongly to endogenous CBFβ
(Figure 1b, upper panels, lanes 1, 5, 9 and 13). In contrast, single
mutations in N or T decreased the AE/CBFβ interaction to a low but
still detectable level (Figure 1b, upper panels, lanes 2, 3, 6, 7, 10 and
11), whereas the NT double point mutations completely abrogated
the interaction (Figure 1b, upper panels, lanes 4, 8, 12 and 14). Of
note, the ETO protein did not interact with CBFβ (Figure 1b, upper
panel, lane 15). The AE9a splice variant is detectable in AML
patients, as RNA-Seq of t(8;21) AML (n=10) as well of 23 patients
with either inv(16) or a cytogenetically normal karyotype with a
NPM1 mutation revealed the expression of the alternative exon E9a
to be mutually exclusive in t(8;21) cases, accounting for approx.
24% of the fusion transcript (Supplementary Figures S1a–c).
Therefore, we focused the study on AE9a.
Considering that the NT mutations lie within the DNA-binding
Runt-domain of AML1,6 we next evaluated the DNA-binding ability
of AE9aNT. Electromobility shift assays revealed that the NT
mutated Runt domain (Runt NT, Figure 1c, lanes 5 and 6) as well as
AE9aNT (Figure 1c, lanes 13 and 14) still possess DNA-binding
capacity, but to a lower extent compared to the wt Runt domain
(Figure 1c, lanes 3 and 4) and AE9a (Figure 1c, lanes 11 and 12),
respectively. Western blot analysis showed almost equal levels of
protein expression (Supplementary Figures S1d and e), thereby
ruling out that the observed differences might be simply due to
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different protein levels. Altogether, these data suggest that the NT
mutation within the Runt domain of AE9a reduces, but does not
abrogate, its DNA-binding ability.
AE9a and AE9aNT show different subnuclear localization
To determine whether AE9a and AE9aNT localize distinctly, cells
transiently transfected with GFP-tagged AE9a or AE9aNT alone
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(AE9a-GFP or AE9aNT-GFP) or together with mRuby-tagged
CBFβ (CBFβ-mRuby) were analyzed by ﬂuorescence microscopy
(Supplementary Figure S2) and confocal laser scanning micro-
scopy (Figure 2). Both AE9a and AE9aNT localized to the nucleus
(Supplementary Figure S2 and Figures 2a–c). A closer inspection
by confocal laser scanning microscopy revealed that AE9a
appeared punctuated and highly structured in a speckled pattern
(Figures 2a and b), consistent with previous reports suggesting
that AE is associated with the nuclear matrix.39,40 In contrast,
AE9aNT presented with a homogenous localization throughout
the nucleus (Figures 2a and b). In addition, in the presence of
AE9a-GFP, CBFβ-mRuby was detected in the nucleus with virtually
no signal in the cytoplasm (Figure 2b, upper panel, middle
column and Figure 2c) while, in the presence of AE9aNT-GFP, the
distribution of CBFβ-mRuby was, as expected, not restricted
to the nucleus (Figure 2b, middle panel, middle column and
Figure 2c) and very similar to the distribution in cells transfected
with CBFβ-mRuby alone (Figure 2b, lower panel, middle column,
Figure 2c). AE9aNT thus failed to retain CBFβ in the nucleus.
Altogether, these data suggest that the AE9a/CBFβ interaction has
a dual function: while CBFβ stabilizes the DNA binding of AE9a, as
previously described in the case of AML1,41 AE9a supports the
nuclear localization of CBFβ.
AE9a but not AE9aNT interferes with RBP-J/SHARP-mediated
repression of Notch target genes
We have previously demonstrated that AE interferes with the
endogenous SHARP/ETO-dependent repression of Notch target
genes.31 SHARP, a component of the RBP-J corepressor complex,
physically interacts and co-localizes with ETO as well as AE via its
highly conserved SPOC domain.31 RBP-J is the key transcription
factor that modulates expression of Notch target genes.42,43 We
therefore investigated if the NT mutation in AE9a inﬂuences its
physical/functional binding to SHARP. GST pulldown experiments
using a bacterially puriﬁed GST-tagged SPOC domain (amino acids
3477–3664) and in vitro transcribed/translated AE9a, AE9aNT or
ETO as positive control revealed that GST-SPOC interacts with
both AE9a and AE9aNT in cell-free assays (Figure 3a, right panel).
The interaction was further validated by coimmunoprecipitation
experiments using Flag-tagged SPOC and GFP-tagged AE9a or
AE9aNT (Supplementary Figure S3a). We recently reported that an
RBP-SPOC fusion protein acts as a dominant repressor of Notch-
dependent transcription.34 Luciferase assays in HeLa cells using an
RBP-dependent reporter construct and either RBP44 or RBP-SPOC
alone or in combination with ETO, AE9a or AE9aNT revealed that
AE9a, but not AE9aNT or ETO, possesses derepressing activity
(Figure 3b). Interestingly, AE9a-dependent derepression was
reduced in response to expression of the Runt domain but not
of the mutated Runt NT domain defective for CBFβ binding
(Supplementary Figure S3b). Since CBFβ is expressed in HeLa cells
(Supplementary Figure S3c), these data suggest that the AE9a/
CBFβ interaction is a prerequisite for its derepressing activity. To
characterize the AE9a/SPOC interaction in more detail we used
speciﬁc point mutations (Figure 3c) within the SPOC domain of
SHARP.45
We observed that mutations within the SPOC domain of SHARP
(Flag-SPOC (Y3602A), Flag-SPOC(K3516A), Flag-SPOC(R3552A/
R3554A)) strongly reduce the AE9a/SPOC interaction in both
biochemical (Figure 3d) and functional (Figure 3e) analyses.
Altogether, these data support that the SPOC/AE9a/CBFβ interac-
tion is required for derepressing promoter elements bound by
RBP-J, further implying that AE9a is not just a dominant negative
form of AML1.
Differential requirement of the AE9a/CBFβ interaction in
deregulating gene expression
AE9a, but not AE9aNT, when expressed in hematopoietic
progenitor cells immortalized by overexpression of HoxB4 (HoxB4
cells32) leads to derepression of several Notch target genes, such
as Hey1, Hes1, Nrarp, Igf1r and Gpr56 (Figure 3f, left). These effects
are direct, as RBP-J is bound to the Notch-responsive elements of
Hey1, Hes1 and Nrarp in HoxB4 cells (Supplementary Figure S3d
and schematic representation in Supplementary Figure S3e). In
contrast, both AE9a and AE9aNT are able to repress AML1 target
genes Csf1r and Mcm2 and activate Vegfc (Figure 3f, right).
Altogether, these data suggest that the AE9a/CBFβ interaction is
required to derepress Notch target genes but not to deregulate
AML1 target genes.
The AE9a/CBFβ interaction is dispensable to increase the
self-renewal potential of hematopoietic progenitor cells
To test the ability of AE9a and AE9aNT to sustain hematopoietic
self-renewal upon serial rounds of replating, colony-forming
cell assays with retrovirally transduced cells were performed
(overview in Supplementary Figure S4a, expression control in
Supplementary Figure S4b). While, as expected, self-renewing
ability was absent in IRES-GFP control cells (Figure 4a, no colonies
upon replating), both AE9a-IRES-GFP (AE9a) or AE9aNT-IRES-GFP
(AE9aNT) sustained signiﬁcant self-renewing ability, as multiple
rounds of replating still resulted in colonies (Figure 4a) indicating a
strong differentiation block conferred by both AE9a28 and AE9aNT.
Colonies from AE9a transduced cells though presented with a
more immature morphology, whereas AE9aNT colonies contained
a higher frequency of more differentiated mononuclear cells
(Figures 4b and c), consistent with the lower AE9aNT replating
activity compared to AE9a. Altogether these data suggest that
both AE9a and AE9aNT induce self-renewal of progenitor cells but
the differentiation block conferred by AE9aNT might be distinct
from the one induced by AE9a.
The AE9a/CBFβ interaction is required for leukemogenesis
BM transplantation experiments were performed to determine the
in vivo leukemic potential of AE9a and AE9aNT (Supplementary
Figure S4a). BM cells from C57BL/6 Ly5.2 mice were retrovirally
transduced either with IRES-GFP (control), AE9a-IRES-GFP (AE9a) or
AE9aNT-IRES-GFP (AE9aNT) prior to transplantation into recipient
C57BL/6 Ly5.1 (BoyJ) mice. Overall engraftment (Supplementary
Figure S5a) and frequency of GFP+ cells (Supplementary Figure
S5b) was constantly monitored in PB and revealed stable values.
In the transplanted control group (IRES-GFP), three out of nine
Figure 2. Subcellular localization of CBFβ after coexpression of AE9a or AE9aNT. Confocal ﬂuorescent microscopy after cotransfection of HeLa
cells with GFP-tagged AE9a or AE9aNT (AE9a-GFP and AE9aNT-GFP, respectively) together with mRuby-tagged CBFβ (CBFβ-mRuby). (a) AE9a
but not AE9aNT shows a speckled pattern in the nucleus. Representation of green ﬂuorescence intensity as three-dimensional plots
(ﬂuorescence intensities are false color coded). (b) Green channel (AE9a or AE9aNT), red channel (CBFβ) and their overlay in cotransfected
HeLa cells. Scale bar, 10 μm. (c) Fluorescence quantiﬁcation within the nucleus. Intensities of the green (AE9a and AE9aNT) and red (CBFβ)
signals in the nucleus and the cytoplasm were analyzed. Graphs show percentages of signal intensities in the nucleus. Cells were ﬁxed 24 h
after transfection and analyzed by confocal microscopy. Nuclear and cytoplasmic distributions of green and red ﬂuorescence intensities were
measured in 40 cells, respectively. Mean values ± s.d. (error bars) are shown (nsNot signiﬁcant, ***Po0.001, unpaired Student’s t-test).
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animals died within the observation period of 380 days due to
solid tumors or wound infections from skin lesions (Figure 5a, left,
green line). In the AE9aNT group, 3 out of 13 mice died within the
observation period (Figure 5a, left, blue line) but leukemia was
excluded as cause of death (data not shown). In the AE9a group,
mice showed ﬁrst signs of leukemia at 100 days post
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transplantation and animals died of leukemia between day 150
and 200 post transplantation (Figure 5a, left, red line). At 7 months
post transplantation, BM cells from AE9a mice showed a
homogenous population of immature blasts, whereas cells from
AE9aNT mice were more heterogeneous and differentiated
(Figure 5a, right). Analysis of white blood cell (WBC) counts
(Supplementary Figure S6a) and expression of the immature
blast marker c-kit (Figure 5b) further conﬁrmed that AE9a mice
presented an AML-like phenotype. Recipients of AE9a-transduced
BM cells showed elevated WBC as early as 20 weeks post
transplantation (Supplementary Figure S6), paralleled by increased
frequency of c-kit+ cells in the PB (Figure 5b). Mice transplanted
with either control or AE9aNT-transduced BM cells displayed
baseline levels of WBC and low frequencies of c-kit+cells in PB
(Supplementary Figures S6a and 5b, respectively). AE9a-
transplanted mice further presented with splenomegaly (data
not shown), high WBC in the spleen (Figure 5c, left) and high
frequency of c-kit+ cells in BM and spleen (Figure 5c, right). In
addition, BM cells isolated at day 214 post transplantation showed
derepression of Notch targets Hey1, Hes1, Nrarp and Gpr56, but not
Igf1r in AE9a-transduced mice, while BM cells from IRES-GFP
(control) or AE9aNT-transduced mice did not (Supplementary
Figure S6b). Taken together, these data imply that the AE9a/CBFβ
interaction and derepression of Notch target genes via the
interaction with the corepressor SHARP are necessary for initiation
of AML by AE9a.
AE9aNT regulates lymphocyte differentiation and hematopoietic
stem and progenitor cells in vivo
Compared to animals transplanted with empty vector control
(IRES-GFP), AE9aNT-transplanted mice displayed increased fre-
quencies of B220+ B-cells in PB (Figure 6a), which was mirrored by
a reduced frequency of CD3+ T-cells (Figure 6b). AE9aNT might
thus skew the differentiation of common lymphoid progenitor
Figure 3. Both AE9a and AE9aNT interact with the Notch-corepressor SHARP but only AE9a derepresses Notch target genes. (a) AE9a and
AE9aNT interact with the SPOC domain of SHARP. GST pulldown assay was performed by using bacterially puriﬁed GST-SPOC or GST only as
control and cell free synthesized AE9a, AE9aNT or ETO as positive control. (b) AE9a but not AE9aNT derepresses RBP-J-dependent
transcription. Activity of AE9a and AE9aNT was tested in HeLa cells by luciferase assays using the RBP-dependent reporter construct pGA891/6
and RBP or RBP-SPOC fusion proteins together with ETO, AE9a or AE9aNT. Mean values ± SD (error bars) based on at least three independent
experiments are shown (nsNot signiﬁcant, ***Po0.001, unpaired Student’s t-test). (c) Surface view of the human SPOC domain of SHARP
(PDB1OW1). The four amino acids R3554 (red), R3552 (orange), Y3602 (dark red) and K3516 (magenta), which were mutated to alanines are
shown. Approximately 90° views are shown. (d) SPOC domain mutations show decreased interaction with AE9a (upper panel, lanes 3, 4 and 5).
HEK-293 cells were transfected with the indicated expression constructs for Flag-tagged wt SPOC domain [Flag-SPOC(wt)] or mutant SPOC
domains [Flag-SPOC (Y3602A), Flag-SPOC(K3516A) and Flag-SPOC(R3552A/R3554A)] together with an AE9a-GFP expression construct.
Expression was veriﬁed by western blotting for AE9a (middle panel, lanes 2, 3, 4, 5), SPOC(wt) (lower panel, lane 2) and SPOC mutants (lower
panel, lanes 3, 4 and 5). (e) Mutations of the SPOC domain of SHARP compromise the derepressing activity of AE9a. Activity of AE9a was tested
in luciferase assays using the RBPJ-dependent reporter construct pGA891/6 and RBPJ-SPOC fusion proteins together with AE9a. The RBP-SPOC
mutants show decreased AE9a mediated derepression of transcription. Mean values ± SD (error bars) based on four independent
experiments are shown (nsNot signiﬁcant, *Po0.05, **Po0.01, ***Po0.001, unpaired Student’s t-test). (f) The AE9a/CBFβ interaction is
required to dysregulate Notch target genes (left panel) but not AML1 (right panel) target genes in HoxB4 cells. Total RNA from HoxB4 cells
transfected with empty vector (control), AE9a or AE9aNT was reverse transcribed in cDNA and analyzed via qPCR. Data were normalized to the
housekeeping gene TATA-binding protein. The mean ± SD of triplicate experiments is shown (nsNot signiﬁcant, *Po0.05, **Po0.01,
***Po0.001, unpaired Student’s t-test).
Figure 4. Colony forming potential of transduced progenitor populations. See overview in Supplementary Figure S4a. (a) AE9a displays higher
replating efﬁciency compared to GFP control and CBFβ-binding deﬁcient mutant AE9aNT. Colony-forming potential was measured by serial
replating of sorted BM cells expressing IRES-GFP (control), AE9a-IRES-GFP (AE9a) and AE9aNT-IRES-GFP (AE9aNT) on semi-solid methylcellulose
medium in seven days intervals over 5 weeks. Mean values and standard deviation (error bars) based on at least three independent
experiments are shown. (nsNot signiﬁcant, ***Po0.001). (b) Images of representative colonies of AE9a (upper panel) and AE9aNT (lower
panel). (c) Analysis of cells in the colonies of AE9a (upper panel) and AE9aNT (lower panel) via Giemsa staining. While AE9a colonies consist of
cells with immature morphology, AE9aNT colonies contain a higher number of mononuclear cells with a massive cytoplasmatic incorporation
of methylcellulose (bars, 100 μm). Protein expression of AE9a and AE9aNT in cells isolated from methylcellulose was veriﬁed by western blot
shown in Supplementary Figure S4b.
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cells towards the B-cell lineage. Finally, compared to controls,
we observed an elevated frequency of hematopoietic progenitor
lineage−/sca-1−/c-kit+ (L−S−K+) cells, granulocyte/macrophage
progenitors (GMP), common myeloid progenitors (CMP), and
megakaryocyte-erythrocyte progenitors (MEP) in AE9aNT BM 2
years post transplantation (Figure 6c), implying that AE9aNT might
also support enhanced self-renewal properties in vivo, similar to its
enhanced replating ability in vitro (Figure 4a).
Figure 5. AE9a but not AE9aNT causes myeloid leukemia and a typical leukemic differentiation pattern. Upon 5-FU injection, BM progenitor
cells, transduced with either IRES-GFP (control), AE9a-IRES-GFP (AE9a) or AE9aNT-IRES-GFP (AE9aNT), were transplanted into lethally irradiated
(11Gy) C57BL/6 Ly5.1 mice (see overview in Supplementary Figure S4a). (a, left) Kaplan–Meier plot showing that the majority of AE9a
transplanted mice died between day 150 and 200 post transplantation whereas AE9aNT mice and control animals did not succumb to
leukemia. (a, right) Representative images of BM cells stained with Giemsa from AE9a or AE9aNT mice analyzed 214 days post-transplantation.
While AE9a mice presented with homogenous population of immature blasts, AE9aNT BM cells contained heterogenous and differentiated
populations. (b) c-kit expression in GFP+ cells in PB was monitored at 6–8 weeks intervals via ﬂow cytometry. AE9a transplanted mice
displayed signiﬁcantly elevated c-kit+ cell numbers compared to GFP or AE9aNT transplanted mice over the entire observation period.
(nsNot signiﬁcant, *Po0.05, **Po0.01, unpaired Student’s t-test). (c) Analysis of spleen and BM cells 214 days post-transplantation. (c, left)
WBC counts from the spleen of mice transplanted with AE9a (red) are signiﬁcantly elevated compared to mice transplanted with GFP (control,
green) and AE9aNT (blue) (nsNot signiﬁcant, **Po0.01, unpaired Student’s t-test, k= 103). Mean values based on the number of animals.
(c, right) Flow cytometric analysis of c-kit expression in BM and spleen of representative GFP (control, green), AE9a (red) and AE9aNT (blue)
transplanted mice indicate a higher percentage of c-kit+ cells in BM and spleen of AE9a transplanted mice.
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DISCUSSION
The molecular mechanisms of the contribution of AE to AML
initiation are still not fully understood.5,25,46 Yan et al.27 showed
that only a truncated version of AE (AEtr) but not the full-length
fusion protein was able to induce leukemia in a murine
transduction/transplantation model. They further identiﬁed a
Figure 6. Analysis of PB composition of AE9a and AE9aNT mice at indicated time points post transplant. (a) Levels of B220+ cells within the
GFP positive/Ly5.1− cell population. (b) CD3+ cells within the GFP+ /Ly5.1− cell population in PB over time (nsNot signiﬁcant, *Po0.05,
**Po0.01, unpaired Student’s t-test). Mean values based on the number of animals. (c) Flow cytometric measurement of myeloid progenitor
cells (lineage−/Sca-1−/c-kit+ [L−S−K+]), granulocyte/macrophage progenitors (GMP); (CD16/32+, CD34+), CMP (common myeloid progenitors;
CD16/32−, CD34+) and megakaryocyte-erythrocyte progenitors (MEP); (CD16/32−, CD34−) in the GFP+ BM cell population of control (green)
and AE9aNT (blue) transplanted mice after approximately 2 years post transplantation. Mean values based on the numbers of animals.
Notch target genes contribute to AML
VN Thiel et al
2499
Leukemia (2017) 2491 – 2502
shorter, spliced isoform of AE (AE9a) in AML patients that is
structurally similar to the truncated AE product and also strongly
induces leukemia in the transduction/transplantation model28
(and see Figure 5). Given that AML patients coexpress both the
full-length AE and the AE9a variant at ratios that are very distinct28
(and Supplementary Figures S1a–c) the ‘personal’ AE/AE9a ratio
might have a signiﬁcant impact on the aggressiveness of
the leukemia. In line with that, high levels of AE9a in patients
indicate a poor disease outcome.47 However, the underlying
mechanisms of AE9a-mediated leukemogenesis remain to be
elucidated. The structure of AE9a though argues against a model
in which AE simply converts the AML1 activator into an AE
repressor, since AE9a is a weaker repressor compared to AE and
the speciﬁc disruption of the NHR4 region of AE that is also
deleted in AE9a (see also Figure 1a) reduces the interaction with
corepressors nuclear receptor corepressor 1 and SMRT.12,11
Our study for the ﬁrst time demonstrates that deregulation of
both AML1 target genes as well as Notch target genes by AE9a is
required for AML initiation. Notch1-activating mutations were
previously shown to either act as an oncogene48,49 or in other
instances as a tumor suppressor.50 Previous studies postulate a
negative role of Notch signaling in myeloid leukemia.51 In an
animal model of AML, Notch gain of function induced rapid cell
cycle arrest, differentiation and apoptosis of AML-initiating cells.52
However, our data support the notion that derepression of Notch
target genes, due to interference with the RBP-J corepressor
complex, facilitates the development of leukemia. This is in
agreement with a previous study showing that AE expression
leads to upregulation of Notch target gene.53 In addition to our
ChIP data, we have also analyzed anti-AE ChIP-Seq data previously
published by the Stunnenberg lab54 and observed that AE
localizes at the Notch-responsive elements of Hes1 and Hey1
(Supplementary Figure S7).
Moreover, we show that binding of AE9a to the coactivator
CBFβ is necessary for leukemia initiation (Figure 5). Two previous
studies already analyzed the role of CBFβ in AE’s activity by
mutating Y113A/T161A23 or M106V22 within the Runt domain of
AE. Whereas Kwok et al.22 observed no need for interaction with
CBFβ the study from Roudaia et al.23 showed absolute require-
ment for leukemogenesis. Based on structural analysis, we
decided not to use the same mutations but instead the double-
mutant AE9a-N109A/T161A (AE9aNT) that did not show any major
effects in protein stability compared to the wt AE9a protein. In
regard to expression of AML1 target genes, our data show no
differences between AE9a and the CBFβ-binding defective mutant
AE9aNT, agreeing with Kwok et al. On the other hand, there are
clear differences observed between AE9a and AE9aNT when
expression of Notch target genes is analyzed, in agreement with
the study by Roudaia et al. Regarding leukemogenesis, we do
observe that overexpression of AE9a but not AE9aNT results in
leukemia, agreeing with Roudaia et al. However, we do observe
features of myeloproliferation not only in AE9a but also in AE9aNT.
Furthermore, the functionality of both AE9a and AE9aNT is also
observed in the T-cell lineage given that levels of peripheral T-cells
are reduced in animals transplanted with either AE9a or AE9aNT.
These data further support that AE9aNT is a functional protein.
To note, at the same time, AE9a, and even more AE9aNT, leads
to increased B-cell frequencies, suggesting wide hematopoietic
defects conferred by these fusion proteins and furthermore
suggesting a distinct functionality of AE9aNT. It remains to be
established whether this observation might serve as a novel
diagnostic tool to better characterize and identify distinct forms
of AML.
In summary, we show that AE9a but not the CBFβ-binding
deﬁcient mutant AE9aNT mediates leukemogenesis in vivo.
However, both AE9a and AE9aNT are active in replating assays
indicating functional progenitor self-renewal. At the molecular
level, interaction of AE9a with CBFβ is a pre-requisite for AE9a
to dysregulate Notch target genes but not AML1 target genes
(see Table 1 for summary). Therefore, our data demonstrate a
signiﬁcant role for aberrant regulation of Notch signaling in
leukemia initiation by AE9a.
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